For the first time, the FDA has approved a drug—KeyTruda—for cancer-based disease genetics rather than the site of a tumor. KeyTruda now can be used for colon, pancreatic, stomach, ovarian and other cancers if genetic testing reveals defects in so-called mismatch repair. The clinical trials for KeyTruda were conducted at the Johns Hopkins Bloomberg-Kimmel Institute. Swim Across America was the first organization to believe in the KeyTruda research project and provide grant funding for KeyTruda clinical trials. In total, over $2.6 million in proceeds from SAA—Baltimore have funded clinical trials and lifesaving research at Johns Hopkins.
You can make a credit card donation by clicking on one of the members of our team below, or send a check to Swim Across America, PO Box 217, Larchmont, NY 10538.
Check should be made out to Swim Across America but please include a note mentioning our team or the swimmer you are supporting!